UnitedHealth Group Incorporated (NYSE:UNH) is a very different valuation story than it was a few years ago. The stock used to command the kind of premium multiple investors were willing to pay for a high-quality healthcare compounder. That premium has largely disappeared after a difficult stretch of higher medical costs and pressure across parts of its insurance business.
That raises a more interesting question for investors today: Has UnitedHealth’s forward P/E fallen enough to account for the problems weighing on the stock? The company has two major businesses that complement each other. UnitedHealthcare provides health insurance and benefits, while Optum operates across healthcare delivery, pharmacy services, data, technology, and analytics. Together, they give UnitedHealth a presence across several parts of the healthcare system that most competitors simply cannot match. It is among the most popular healthcare stocks according to hedge funds, but one stock ranks even higher on their radars.
The company’s advantage goes beyond its size. UnitedHealth Group Incorporated can use information from its insurance business to improve how care is delivered, while Optum gives it exposure to healthcare services and technology outside traditional insurance. Its huge network of customers, providers, and healthcare relationships would also be extremely difficult for a smaller rival to build from scratch. There’s another healthcare stock to hold in rough markets, and it has gained over 60% over the past year. Check here.
The P/E tells the real story
UnitedHealth’s latest results suggest that the business may finally be starting to stabilize. In the second quarter of 2026, revenue reached $112.0 billion, while adjusted earnings came in at $6.38 per share. More importantly, management raised its full-year 2026 adjusted earnings guidance to $19.50-$20.00 per share. Operating cash flow was $11.1 billion for the quarter.
Yet the stock is still trading at a much lower valuation than it was earlier in the year. UNH had a 23.97x trailing P/E and a 16.58x forward P/E as of September 22, 2026. The forward multiple is the more important number here because it reflects what investors are paying for the earnings the company is expected to generate. The change becomes even more noticeable when looking at earlier valuations. Yahoo Finance showed a 31.30x trailing P/E and 22.78x forward P/E at the end of June, compared with 17.20x and 18.66x, respectively, at the end of 2025. So investors have clearly become less willing to pay a premium for UnitedHealth. This raises the question of whether the stock’s lower valuation is an opportunity or a value trap. Find here.
That alone does not mean the stock is cheap. A falling P/E can be perfectly reasonable when a company’s earnings outlook deteriorates. The important question is whether the current multiple already reflects most of the concerns surrounding UnitedHealth. At 16.58x forward earnings, the stock has a forward earnings yield of roughly 6.0%. That compares with an earnings yield of about 4.2% based on the trailing P/E. Put another way, investors buying the stock today are paying about $16.58 for every dollar of expected future earnings, rather than nearly $24 for every dollar of earnings the company generated over the trailing period. That is a meaningful difference.
UnitedHealth also offers a 2.45% forward dividend yield. That yield isn’t particularly high on its own, but the bigger point is that the company’s earnings are substantially higher than what it pays out in dividends. That leaves the company with cash to reinvest in the business, reduce debt, or return additional capital to shareholders. If earnings recover as management currently expects, that combination could become increasingly attractive.
Is the discount justified?
This is where investors need to be careful.UnitedHealth is not out of the woods yet. Medical costs remain a concern, reimbursement pressures could continue, and regulatory uncertainty hasn’t disappeared. The next earnings report will therefore be important, particularly because the company is scheduled to report third-quarter results on October 13.
Still, the current valuation gives investors more room for error than they had when UnitedHealth traded at a much higher multiple. A 24x trailing P/E doesn’t immediately look like a bargain. But a 16.6x forward P/E tells a different story, particularly for a company with UnitedHealth’s scale, diversified operations, and long-term earnings potential.
The stock also doesn’t need to return to its old premium valuation for investors to earn solid returns. If earnings recover and the market is willing to value those earnings at a mid-to-high teens multiple, investors could benefit from a combination of earnings growth, dividends, and some multiple expansion.
That’s what makes UnitedHealth interesting at its current price. The bull case isn’t that the stock suddenly returns to its old premium valuation. It’s that the current forward P/E may already be pricing in a large part of the bad news, leaving room for the valuation to recover if the underlying business does the same.
READ NEXT: Royal Caribbean Group: Has the Market Already Priced in the Cruise Recovery? and Kraft Heinz Stock Looks Cheap. Here’s What Investors are Missing
This article is originally published at Insider Monkey.
Hedge Fund Resource Center